JUSTTHENEWS (Kevin Killough) - FDA approves updated COVID vaccines for 2026-27 season
All manufacturers said they'll have vaccines read for the 2026-27 immunization season.
WASHINGTONPOST (Daniel Wu) - FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
NYTIMES (Gina Kolata and Rebecca Robbins) - F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
YOUTUBE (Fox Business) - VACCINE BREAKTHROUGH: Personalized cancer treatment takes major leap
Moderna CEO Stéphane Bancel joins ‘Mornings with Maria’ to discuss the company's landmark cancer vaccine partnership with Merck. Bancel details the promising Phase 3 melanoma trial results and outlines Moderna's latest financial growth outlook. #foxbusiness #morningswithmaria 0:03 – Moderna and Merck’s Personalized Cancer Vaccine Breakthrough 1:18 – Moderna Targets FDA Approval for Next Year 2:20 – Expanding mRNA Cancer Treatment Beyond Melanoma 5:21 – Moderna’s mRNA Push: Rare Diseases and a New Flu Vaccine 7:27 – Personalized Vaccine Costs, Manufacturing and Moderna’s Growth Outlook
BITCHUTE (The Corbett Report) - Guess Where They're Building Data Centres Now... - New World Next Week
SHOW NOTES AND MP3: https://corbettreport.com/nwnw640/ This week on New World Next Week: the FDA approves mRNA flu shot slurry; apple falls close to Gates family tree; and grow ops to data centers. ARE YOU LOOKING FOR SHOW NOTES WITH LINKS TO ALL OF THE ARTICLES, VIDEOS AND WEBSITES MENTIONED? HOW ABOUT COMMENTS? THEY’RE AT THE CORBETT REPORT WEBSITE! JUST FOLLOW THE “SHOW NOTES AND COMMENTS” LINK ABOVE TO GO THERE DIRECTLY.
JUSTTHENEWS (Greg Piper) - Science by press release: Moderna cashes in on mRNA cancer vaccine without publishing trial results
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins cardiology operations chief says after Moderna share price spikes. Its mRNA flu vaccine trial data are still hidden.
YOUTUBE (MS NOW) - The Night Light: A new hope for cancer patients
Personalized vaccines could be around the corner thanks to decades of work by doctors like Michelle Wu. Her story and details on the new breakthrough on tonight's 11th Hour with Ali Velshi.
YOUTUBE (The Hill) - NRCS warns data center boom has become a ballot box liability in OH - The Hill | NEWSNATION
Host Blake Burman discusses a new warning from the National Republican Senatorial Committee that says data centers have become a ballot box liability in Ohio's Senate race, as President Trump calls the centers and AI good for jobs, innovation, and the economy. Meanwhile, in Tuesday's primary races in Florida, several far-left candidates delivered surprise results. 00:00 -- Introduction 01:28 -- NRCS warns data centers could sink race 12:30 -- mRNA vaccine shows promise against cancer 19:57 -- Trump pauses 50% tariffs on Canada 29:05 -- NASA reveals SpaceX rocket crash crater 36:08 -- Bear encounters rise from East to West
YOUTUBE (NewsNation) - Inside the new experimental cancer vaccine doctors are calling ‘a big deal’
Moderna and Merck announced this week that an experimental vaccine for melanoma patients showed positive initial results. Dr. Mahsa Tehrani joins “Elizabeth Vargas Reports” to explain the mRNA technology behind the potential breakthrough. #Health #Cancer #mRNA Anchor Elizabeth Vargas delivers the biggest stories, without bias or opinion. Watch "Elizabeth Vargas Reports" every weeknight at 7p/6C on NewsNation. #VargasReports NewsNation is your source for fact-based, unbiased news for all Americans.
AXIOS (Tina Reed) - Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. - The customized therapy, which could see a commercial launch next year, could also be adapted for other cancers of the kidney, bladder and pancreas. The big picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined…